Levamlodipine/Bisoprolol

To evaluate the efficacy and safety of levoamlodipine-bisoprolol tablets in patients with essential hypertension whose blood pressure is poorly controlled after monotherapy with levoamlodipine besylate tablets or bisoprolol fumarate tablets.

Main objective: To compare the pharmacokinetic parameters as the primary endpoint evaluation indicators, and to compare the pharmacokinetic behavior of the test preparation T levamlodipine bisoprolol tablets (specification: 2.5mg/5mg (calculated as levamlodipine/bisoprolol fumarate), manufacturer: Shi Huida Pharmaceutical Group (Jilin) Co., Ltd.) and the control preparations R1 levamlodipine besylate tablets (specification: 2.5mg (calculated as levamlodipine), license holder: Shi Huida Pharmaceutical Group (Jilin) Co., Ltd., trade name: Shi Huida®) and R2 bisoprolol fumarate tablets (specification: 5mg, license holder: Merck Pharmaceuticals (Jiangsu) Co., Ltd., trade name: Kangxin®) in healthy subjects after a single oral administration in the fasting/postprandial state, so as to verify whether the absorption rate and extent of the combination preparation levamlodipine bisoprolol tablets and the single drug levamlodipine besylate tablets and bisoprolol fumarate tablets are consistent in healthy subjects. Secondary objective: To observe the safety of a single oral administration of the test formulation T levamlodipine bisoprolol tablets in healthy subjects.